For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Tafamidis meglumine represents a genuine change. These innovative therapies protect the transthyretin protein, preventing its destructive build-up and reducing the im